Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
ALC 
Alcon AG (ALC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/25/2026: ALC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
27 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $91.8
1 Year Target Price $91.8
| 15 | Strong Buy |
| 6 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 41.48B USD | Price to earnings Ratio 40.06 | 1Y Target Price 91.8 |
Price to earnings Ratio 40.06 | 1Y Target Price 91.8 | ||
Volume (30-day avg) 27 | Beta 0.69 | 52 Weeks Range 71.55 - 98.85 | Updated Date 02/25/2026 |
52 Weeks Range 71.55 - 98.85 | Updated Date 02/25/2026 | ||
Dividends yield (FY) 0.40% | Basic EPS (TTM) 2.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-03-03 | When - | Estimate 0.7843 | Actual 0.78 |
Profitability
Profit Margin 10.28% | Operating Margin (TTM) 12.85% |
Management Effectiveness
Return on Assets (TTM) 2.62% | Return on Equity (TTM) 4.82% |
Valuation
Trailing PE 40.06 | Forward PE 20.96 | Enterprise Value 41024467443 | Price to Sales(TTM) 4.07 |
Enterprise Value 41024467443 | Price to Sales(TTM) 4.07 | ||
Enterprise Value to Revenue 4.09 | Enterprise Value to EBITDA 14.95 | Shares Outstanding 491200000 | Shares Floating 490040768 |
Shares Outstanding 491200000 | Shares Floating 490040768 | ||
Percent Insiders 0.21 | Percent Institutions 67.51 |
Upturn AI SWOT
Alcon AG
Company Overview
History and Background
Alcon was founded in Fort Worth, Texas, in 1945 by William Conner and Robert Alexander. Initially a small pharmaceutical laboratory, it grew to become a global leader in eye care. In 2019, Alcon was spun off from Novartis to become an independent, publicly traded company. Its focus remains on advancing eye care through innovative products and services.
Core Business Areas
- Surgical: This segment offers a comprehensive portfolio of products for ophthalmic surgery, including advanced surgical equipment, intraocular lenses (IOLs), and consumables used in procedures such as cataract, refractive, and vitreoretinal surgery.
- Vision Care: This segment is dedicated to contact lenses and ocular health products. It includes daily disposable, reusable, and toric contact lenses, as well as lens care solutions and dry eye treatments.
Leadership and Structure
Alcon is led by a Board of Directors and an Executive Leadership Team. The CEO is David Endicott. The company operates globally with a matrix organizational structure to manage its diverse product lines and geographic regions.
Top Products and Market Share
Key Offerings
- Cataract Surgical Solutions: Includes intraocular lenses (IOLs) like AcrySof IQ, refractors, and surgical equipment. Alcon is a leading provider in the global cataract surgery market. Competitors include Johnson & Johnson Vision, Carl Zeiss Meditec, and Bausch Health Companies.
- Contact Lenses: Features brands such as Dailies AquaComfort Plus, Air Optix, and Total30. Alcon is a significant player in the global contact lens market. Key competitors include Johnson & Johnson Vision, CooperCompanies, and Bausch Health Companies.
- Ophthalmic Pharmaceuticals: Offers a range of prescription eye drops for conditions like glaucoma and infections. While not their largest segment, it's a key part of their integrated eye care offering. Competitors include AbbVie, Bayer, and Takeda Pharmaceutical.
Market Dynamics
Industry Overview
The global eye care market is characterized by a growing and aging population, increasing prevalence of eye diseases, rising adoption of advanced surgical technologies, and demand for convenient vision correction solutions like contact lenses.
Positioning
Alcon is positioned as a pure-play global leader in eye care, offering a comprehensive portfolio across both surgical and vision care segments. Its strengths lie in its strong brand recognition, extensive product pipeline, global distribution network, and commitment to innovation.
Total Addressable Market (TAM)
The global ophthalmic devices market is substantial and projected to grow significantly. Alcon is well-positioned to capture a significant portion of this TAM through its broad product offerings and established market presence in both surgical and vision care segments.
Upturn SWOT Analysis
Strengths
- Leading global position in eye care
- Diversified product portfolio across surgical and vision care
- Strong brand recognition and reputation
- Significant investment in R&D and innovation
- Extensive global distribution network
Weaknesses
- Dependence on a few key product lines
- Competition from larger diversified healthcare companies
- Integration challenges following spin-off from Novartis
- Potential for pricing pressures
Opportunities
- Growing demand for refractive surgery
- Expansion in emerging markets
- Development of new contact lens technologies
- Strategic acquisitions to broaden portfolio
- Increasing adoption of digital health solutions in eye care
Threats
- Intense competition
- Regulatory changes and compliance costs
- Economic downturns impacting elective procedures
- Advancements in competing technologies
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- Johnson & Johnson (US Stock Symbol: JNJ) - Vision segment
- CooperCompanies (US Stock Symbol: COO)
- Carl Zeiss Meditec AG (XTRA: AFX) - although not a US stock, a major competitor globally
- Bausch Health Companies Inc. (US Stock Symbol: BHC)
Competitive Landscape
Alcon holds a strong position due to its comprehensive portfolio and innovation. Its advantages include its focus as a pure-play eye care company. Weaknesses relative to competitors might arise from the scale of R&D budgets of larger diversified companies or specific technological leads held by niche players.
Major Acquisitions
WaveTec Vision
- Year: 2017
- Acquisition Price (USD millions): 405
- Strategic Rationale: To strengthen its position in femtosecond laser technology for cataract surgery.
PRECITE
- Year: 2021
- Acquisition Price (USD millions):
- Strategic Rationale: To enhance its ability to deliver customized optical solutions for lens implantation.
Growth Trajectory and Initiatives
Historical Growth: Alcon has demonstrated consistent growth, driven by its strong product pipeline and strategic expansion. Historical revenue figures and market share gains illustrate its growth path.
Future Projections: Analyst estimates for Alcon's future growth are typically based on market trends, new product launches, and the company's strategic initiatives. Projections often focus on revenue growth, profitability, and EPS expansion.
Recent Initiatives: Recent initiatives likely include the launch of new ophthalmic devices and lenses, expansion into new geographic markets, and investments in digital health solutions to enhance patient care and physician engagement.
Summary
Alcon AG is a leading pure-play eye care company with strong positions in both surgical and vision care. Its diversified product portfolio, commitment to innovation, and global reach are significant strengths. While facing intense competition and potential pricing pressures, Alcon is well-positioned to capitalize on the growing demand for eye care solutions, particularly in emerging markets and through advancements in surgical and contact lens technology.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Alcon AG Investor Relations
- Annual Reports (10-K)
- Financial News Outlets
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute financial advice. Market share data and acquisition prices are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alcon AG
Exchange NYSE | Headquaters - | ||
IPO Launch date 2019-04-09 | CEO & Director Mr. David J. Endicott | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 25000 | Website https://www.alcon.com |
Full time employees 25000 | Website https://www.alcon.com | ||
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, grieshaber, MIVS instruments, scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.